Clinical Trials Logo

Kidney Neoplasms clinical trials

View clinical trials related to Kidney Neoplasms.

Filter by:

NCT ID: NCT00293527 Withdrawn - Renal Cancer Clinical Trials

Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma

Start date: n/a
Phase: Phase 2
Study type: Interventional

This study will determine the response rate of daily low dose interferon-alpha-2b in patients with metastatic or unresectable clear cell renal cell carcinoma.

NCT ID: NCT00293501 Active, not recruiting - Kidney Cancer Clinical Trials

Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Start date: December 2005
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Tinzaparin may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects of tinzaparin and to see how well it works in treating patients with metastatic kidney cancer that cannot be removed by surgery.

NCT ID: NCT00289146 Terminated - Kidney Cancer Clinical Trials

Comparison of Immune Response Following Surgical Management of Renal Tumors

Start date: November 2005
Phase: N/A
Study type: Observational

Examine the effects of renal surgery on the immune system.

NCT ID: NCT00282048 Completed - Clinical trials for Carcinoma, Renal Cell

Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer

Start date: March 2006
Phase: Phase 2
Study type: Interventional

To determine the activity and response rate of AG-013736 in patients with advanced and refractory renal cell cancer, (patients who also failed on sorafenib-based therapy).

NCT ID: NCT00278174 Completed - Kidney Cancer Clinical Trials

Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer

Start date: February 2005
Phase: Phase 2
Study type: Interventional

RATIONALE: Interferon alfa may interfere with the growth of tumor cells and slow the growth of kidney cancer. PURPOSE: This phase II trial is studying how well interferon alfa works in treating patients with metastatic kidney cancer.

NCT ID: NCT00276835 Completed - Kidney Cancer Clinical Trials

Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer

Start date: November 2005
Phase: Phase 0
Study type: Interventional

RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Interleukin-2 may stimulate the white blood cells, including natural killer cells, to kill melanoma or kidney cancer cells. Giving genistein together with interleukin-2 may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving genistein together with interleukin-2 works in treating patients with metastatic melanoma or kidney cancer.

NCT ID: NCT00276614 Completed - Kidney Cancer Clinical Trials

Bortezomib in Treating Patients With Metastatic Kidney Cancer

Start date: April 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with metastatic kidney cancer.

NCT ID: NCT00262886 Completed - Kidney Cancer Clinical Trials

Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer

Start date: August 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: A peripheral stem cell transplant or bone marrow transplant from a brother or sister may be an effective treatment for kidney cancer. PURPOSE: This phase II trial is studying how well a donor peripheral stem cell or bone marrow transplant works in treating patients with relapsed or refractory metastatic kidney cancer.

NCT ID: NCT00243009 Terminated - Kidney Cancer Clinical Trials

Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Start date: June 2005
Phase: Phase 2
Study type: Interventional

RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well giving fludarabine together with total-body irradiation works in treating patients who are undergoing a donor stem cell transplant for metastatic kidney cancer that cannot be removed by surgery.

NCT ID: NCT00241163 Completed - Clinical trials for Surgical Resection of Superficial Renal Tumour

TachoComb S Versus Standard Surgical Treatment in Surgical Resection of Renal Tumour (TC-015-IN)

Start date: n/a
Phase: Phase 3
Study type: Interventional

The overall objective is to compare efficacy and safety of TachoComb S and standard surgical treatment for the control of local bleeding in patients undergoing surgical resection of renal tumours. Specific objectives include the comparison between test treatments of intra-operative haemostatic efficacy as well as post-operative blood loss, haematoma formation, and surgeon's rating of usefulness of test treatment.